NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Phillips DiPisa

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Phillips DiPisa’s Kevin Carroll Co-Authors Article in The Monitor - Kevin Carroll, a Phillips DiPisa associate, co-authors an article that appears in a leading pharmaceutical trade publication, The Monitor, in its September, 2007 issue. The article is entitled, “An Executive Recruiter’s Perspective on Hiring for CRP
Phillips DiPisa’s Kevin Carroll Co-Authors Article in The Monitor

 

NewswireTODAY - /newswire/ - Hingham, MA, United States, 2007/09/28 - Kevin Carroll, a Phillips DiPisa associate, co-authors an article that appears in a leading pharmaceutical trade publication, The Monitor, in its September, 2007 issue. The article is entitled, “An Executive Recruiter’s Perspective on Hiring for CRP.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Phillips DiPisa, an executive search firm serving life sciences, healthcare providers and managed care organizations, today announced that one of its associates, Kevin Carroll, has co-authored an article. The Monitor, a leading pharmaceutical trade publication, published this piece in its September, 2007 issue. The article is entitled, “An Executive Recruiter’s Perspective on Hiring for CRP, Pharmaceutical, and Biotechnology Companies.”

The article offers perspectives on how executive recruiting and search firms need to adapt to meet the challenges of the ever-evolving pharmaceutical industry. It considers the trends and changing practices that affect executive search firms and their clients in the drug development arena.

Kevin Carroll leads the life sciences practice at Phillips DiPisa. He has thirteen years of executive recruiting and sales experience in the pharmaceutical, biotechnology and medical device industries. He focuses on searches for senior executives for commercial, medical and clinical research roles.

Kevin Carroll co-authored this article with Jeff Souza, who leads the commercial staffing business in North and South America for i3 Pharma Resourcing.

About Phillips DiPisa

Phillips DiPisa (phillipsdipisa.com) recruits leaders for healthcare providers, managed care organizations and life sciences firms. The firm’s roots are in Greater Boston – a historical center of medical innovation and excellence. Phillips DiPisa now serves clients along the East Coast and throughout the Midwest, and draws on a national pool of candidates.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Phillips DiPisa

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Phillips DiPisa’s Kevin Carroll Co-Authors Article in The Monitor

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Beth Mills - PhillipsDiPisa.com 
781-740-9699 bamills[.]phillipsdipisa.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Phillips DiPisa securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Phillips DiPisa / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

SCHOTT Pharma Opens Production Facility in Serbia to Strengthen Competitiveness in Europe
NEC Has Developed Technologies that Enable A Secure Workflow for Personalized Cancer Vaccines and Has Proven their Capabilities
BASF Aroma Ingredients Innovates with Two New Isobionics® Biotech Flavor Ingredients
Federal Government Invests .9 Million in STEMCELL Technologies Canada, Inc.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges
Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-class MAIT Cell Engager in Immuno-oncology
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry through Consistent Quality Assurance, On-time Delivery
Bylvay® (odevixibat) Data Shows Sustained Improvement in Severe Itch and Serum Bile Acid Levels in Patients with PFIC and ALGS
Genome BC, STEMCELL Technologies and UBC Partner to Accelerate the Ability to Develop Stem Cells
PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI Diagnosis with its Microarray Detection Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Enciris Technologies

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)